vendredi 31 août 2018

Onco Actu du 31 août 2018

1. Biologie

Children’s bone cancers could remain hidden for years before diagnosis [Wellcome Sanger Institute]

2. Etiologie

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on FDA’s ongoing investigation into valsartan impurities and recalls and an update on FDA’s current findings [FDA]

FDA widening probe into heart drugs linked to cancer risk [STAT]

4.12 Biopsies liquides

A Model Based on Serial Liquid Biopsy Sampling May Predict Time to Progression in Patients With Colorectal Cancer [AACR]

5.1 Traitements - Pré-clinique

Study of Rare Cancer Yields Therapeutic Clues to Combat Drug Resistance [Brigham and Women's Hospital]

5.12 Immunothérapies

FDA Workshop to Address Need for Non-clinical Models to Advance Immuno-oncology [Cancer Research Catalyst]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Sequoia leads $7M seed round for T-cell player RootPath [FierceBiotech]

RootPath Raises $7M to Bring Cancer Cell Therapy to Solid Tumors [Xconomy]

5.12.3 Immunothérapies-combinaisons

Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients [EMA]

5.12.8 Immunothérapies - Economie

Engineered cell therapy given initial ‘no’ for NHS in England [Cancer Research UK]

5.2 Pharma

U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [BMS]

5.3 Traitements - FDA, EMA, NICE...

FDA starts pilot to help sponsors use novel trial designs [FierceBiotech]

Towards improving the availability of medicines in the EU [EMA]

FDA launches pilot program in support of complex trial designs for drugs and biologics [EndPoints]

6.1 Observation

For Nursing Home Patients, Breast Cancer Surgery May Do More Harm Than Good [KHN]

6.10 Politiques

‘No-deal’ Brexit: what the Government’s plans could mean for cancer treatment, care and research [Cancer Research UK]

6.6 Publications

Financial disclosure lacking in publication of clinical trials [OHSU]

6.9 Controverses

Top UK genomics institute investigates bullying allegations [Nature]